Virtu Financial LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Virtu Financial LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the first quarter, according to its most recent filing with the SEC. The fund purchased 66,441 shares of the company’s stock, valued at approximately $662,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. National Bank of Canada FI lifted its holdings in shares of Recursion Pharmaceuticals by 90.9% in the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares during the last quarter. Wedmont Private Capital grew its position in Recursion Pharmaceuticals by 11.8% in the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after buying an additional 2,000 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $26,000. Arizona State Retirement System lifted its stake in Recursion Pharmaceuticals by 8.5% during the fourth quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock valued at $394,000 after buying an additional 3,125 shares in the last quarter. Finally, Green Alpha Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 6.7% in the first quarter. Green Alpha Advisors LLC now owns 72,434 shares of the company’s stock worth $722,000 after acquiring an additional 4,563 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.32 during midday trading on Friday, hitting $7.02. 5,498,190 shares of the company’s stock traded hands, compared to its average volume of 6,034,009. The company has a market cap of $1.67 billion, a PE ratio of -4.39 and a beta of 0.83. The stock’s fifty day simple moving average is $8.34 and its 200-day simple moving average is $9.46. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter in the previous year, the business earned ($0.34) EPS. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RXRX shares. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

Insider Activity

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares of the company’s stock, valued at approximately $4,353,265.41. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total value of $97,070.56. Following the sale, the director now directly owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00. Following the transaction, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at approximately $4,353,265.41. The disclosure for this sale can be found here. Insiders have sold a total of 202,235 shares of company stock valued at $1,654,400 over the last 90 days. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.